You are here

Viela Bio

Horizon still has a mountain to climb

EP Vantage

Tue, 09/13/22 - 10:39 am

Horizon Therapeutics

Sjögren’s syndrome

Quiet times return for biopharma takeouts

EP Vantage

Wed, 04/14/21 - 09:26 am

Five Prime Therapeutics

Gilead Sciences

Horizon Therapeutics

Jazz Pharmaceutical

Horizon inks $3B deal to buy AstraZeneca spinout Viela for autoimmune drugs

Fierce Biotech

Mon, 02/1/21 - 10:33 am

Horizon Therapeutics

autoimmune disease

AstraZeneca spinoff scores maiden FDA approval, where it will field Alexion competition and an imminent Roche rival

Endpoints

Fri, 06/12/20 - 10:40 am

These 4 Biotechs Have Selling Pressure on the Horizon

Motley Fool

Sun, 03/8/20 - 11:29 pm

Frequency Therpeutics

Aprea Therapeutics

Vir Biotechnology

Three Biotechs Raise $320M in IPOs, Two Others Pass on Wall Street

Xconomy

Thu, 10/3/19 - 10:08 pm

Frequency Therapeutics

Aprea Therapeutics

ADC Therapeutics

Monopar Therapeutics

Led by BioNTech, six biotechs line up for October IPOs

Endpoints

Sat, 09/28/19 - 04:38 pm

ADC Therapeutics

Frequency Therapeutics

Aprea Therapeutics

Monopar Therapeutics

Viela Bio Files for $150 Million IPO

Fri, 08/30/19 - 09:52 am

AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug

Endpoints

Mon, 06/17/19 - 12:21 pm

autoimmune disease

AstraZeneca Spinoff Viela Bio Reports Positive Phase IIb Trial in Rare Disease

BioSpace

Thu, 01/3/19 - 04:13 pm

AstraZeneca spinout bags $250M, pipeline headed by late-phase autoimmune drug

Fierce Biotech

Wed, 02/28/18 - 11:16 am

autoimmune disease